Anti-Mouse VEGFR-2 Antibody (DC101)

Anti-Mouse VEGFR-2 Antibody (DC101) 是一种大鼠来源的抗小鼠 VEGFR2 单克隆抗体,通过阻断 VEGF 与 VEGFR2 的结合来抑制肿瘤血管生成、促进免疫细胞浸润并诱导肿瘤细胞凋亡 (apoptosis),可用于黑色素瘤、肺癌和乳腺癌等多种癌症的研究。
Anti-Mouse VEGFR-2 Antibody (DC101)
产品编号: MS-Z00693 纯度: 99% 分子量: 150 kDa
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
1mg
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
50mg
询价
询价
100mg
询价
询价
(100μg)
询价
询价
(100µg)
询价
询价

产品描述

Anti-Mouse VEGFR-2 Antibody (DC101) 是一种大鼠来源的抗小鼠 VEGFR2 单克隆抗体,通过阻断 VEGF 与 VEGFR2 的结合来抑制肿瘤血管生成、促进免疫细胞浸润并诱导肿瘤细胞凋亡 (apoptosis),可用于黑色素瘤、肺癌和乳腺癌等多种癌症的研究。

生物实验数据

生物活性 Anti-Mouse VEGFR-2 Antibody (DC101) is a rat-derived anti-mouse VEGFR2 monoclonal antibody that inhibits tumor angiogenesis by blocking the binding of VEGF to VEGFR2, promotes immune cell infiltration, and induces tumor cell apoptosis (apoptosis), and can be used for research on various cancers such as melanoma, lung cancer, and breast cancer.
IC50 & Target

VEGFR2

 

体内研究
(In Vivo)

Anti-Mouse VEGFR-2 Antibody (DC101) (1 mg/剂量,腹腔注射,每周两次,持续 4 周) 显著诱携带 253J B-V 肿瘤的雄性无胸腺 BALB/c 裸鼠的肿瘤细胞和内皮细胞凋亡,并显著抑制血管生成。
Anti-Mouse VEGFR-2 Antibody (DC101) (10 mg/kg,腹腔注射,在第 2、5 和 8 天) 显著抑制了携带 H22 肿瘤的雌性 BALB/c 小鼠的肿瘤生长且没有明显的毒性。
Anti-Mouse VEGFR-2 Antibody (DC101) (40 mg/kg,腹腔注射,每三天一次,持续 4 周) 显著抑制了携带 B16-OVA 肿瘤的雌性 C57BL/6 小鼠的肿瘤生长并增加了免疫细胞浸润。
Anti-Mouse VEGFR-2 Antibody (DC101) (40 mg/kg,腹腔注射,每周三次,持续 21 天) 显著抑制表达 HPV8 CER 的转基因小鼠的伤口诱导的肿瘤生长。
Anti-Mouse VEGFR-2 Antibody (DC101) (0.8 mg/小鼠,腹腔注射,每周两次,持续 2-3 周) 抑制 FVB 小鼠和携带 NT2.5 肿瘤的 Neu-N 小鼠的肿瘤生长并增加 T 细胞浸润。
Anti-Mouse VEGFR-2 Antibody (DC101) (100 或 400 μg,腹腔注射,每三天一次,持续 21 天) 显著降低了注射 bFGF 和 VEGF 的雌性 C57BL/6 小鼠的血管生成和内皮细胞数量。
Anti-Mouse VEGFR-2 Antibody (DC101) (800 μg,腹腔注射,每三天一次) 显著抑制各种肿瘤的生长。

Animal Model: 1×106 253J B-V cells injected male athymic BALB/c nude mice (8-12 weeks)
Dosage: 1 mg/dose, combined with Paclitaxel (HY-B0015) 10 mg/kg
Administration: Intraperitoneal injection (i.p.), twice weekly for 4 weeks
Result: Significantly prolonged the survival period of mice.
Significantly reduced tumor microvascular density.
Enhanced apoptosis of tumor cells and endothelial cells.
Animal Model: 2×106 H22 cells injected female BALB/c mice (6-8 weeks, 20 g)
Dosage: 10 mg/kg, combined with CA4 NPs (45 mg/kg) and anti-PD-1 (100 μg/mouse)
Administration: Intraperitoneal injection (i.p.) on day 2, 5 and 8
Result: Increased the number of CD8+ T cells within the tumor.
Significantly improved vascular perfusion.
Reduced the level of IFN-γ and TNF-α.
Had good safety in vivo.
Animal Model: 5×105 B16-OVA cells injected female C57BL/6 mice (6-8 weeks)
Dosage: 40 mg/kg
Administration: Oral gavage (i.g.), once every three days for 4 weeks
Result: Significantly inhibited tumor volume.
Increased infiltration of CD3+ and CD8+ T cells.
Increased infiltration of B cells (CD19+) and dendritic cells (CD11c+).
Enhanced the expression of IFN-γ, perforin, and granzyme B in CD8+ T cells.
Reduced vascular density and increased perivascular cell coverage.
Significantly increased the density of PNAd+HEV and promoted the formation of tertiary lymphoid structures (TLS).
Upregulated PD-L1 expression in tumor cells and CD45+ immune cells, as well as PD-1 expression in CD3+ T cells.
Animal Model: Transgenic mice expressing CER of HPV8
Dosage: 40 mg/kg
Administration: Intraperitoneal injection (i.p.), three times every week for 21 days
Result: Reduced Ki-67+ proliferating cells and CD31+ vascular density.
Animal Model: 5×106 NT2.5 cells injected FVB mice and Neu-N mice
Dosage: 0.8 mg/mouse
Administration: Intraperitoneal injection (i.p.), twice weekly for 2-3 weeks
Result: Increased CD4+ and CD8+ T cell infiltration.
Significantly inhibited tumor volume.
Decreased angiogenesis and increased tumor cell apoptosis.
Animal Model: Female C57BL/6 injected with bFGF (500 ng) and VEGF (10 μg)
Dosage: 100 or 400 μg
Administration: Intraperitoneal injection (i.p.), once every three days for 21 days
Result: Significantly reduced angiogenesis and endothelial cell count in matrigel plug model.
Animal Model: 2×106 Lewis lung cells or 1×105 B16 cells injected female C57BL/6 mice (5-6 weeks), 1×105 4T1 cells injected female BALB/c mice (5-6 weeks), 2×106 A431, SK-RC-29, BxPC-3 or GBM-18 cells injected female athymic nu/nu mice (5-6 weeks)
Dosage: 800 μg
Administration: Intraperitoneal injection (i.p.), once every three days
Result: Significantly inhibited tumor growth.
性状 液体
颜色 Colorless to light yellow

化学信息

分子量 150 kDa

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础